Treatment of levodopa-induced dyskinesias with donepezil.
Stanley N Caroff, Rebecca Martine, Galit Kleiner-Fisman...
https://pubmed.ncbi.nlm.nih.gov/16364675/Actively Recruiting
Led by Corporal Michael J. Crescenz VA Medical Center · Updated on 2019-03-22
10
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are exploring the effects of quitting smoking using varenicline on neurological side effects caused by antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. This 12-week pilot study focuses on 10 smokers with pre-existing tardive dyskinesia who are on stable antipsychotic medication doses. The goal is to find out if stopping smoking with varenicline can reduce these neurological symptoms without worsening other movement-related side effects. Participants will begin the study with a 2-week baseline period to monitor symptoms and smoking habits. Varenicline treatment starts at a low dose and increases over the first two weeks, continuing for the remaining 9 weeks. Participants must stop smoking completely by week 6 and will attend several clinic visits for medication checks and symptom assessments throughout the study. During the study, researchers will regularly assess smoking status using questionnaires and carbon monoxide breath tests. Neurological symptoms will be measured with several rating scales, including the Simpson-Angus Scale and Abnormal Involuntary Movement Scale. Additional evaluations include psychiatric symptoms, cognitive tests, pregnancy tests for women, and monitoring of medication adherence and adverse events. The main outcome is the participants smoking abstinence at 12 weeks, along with changes in smoking amount and neurological side effects.
CONDITIONS
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
S
Stanley N Caroff, MD
R
Rosalind M Berkowitz, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Corporal Michael J. Crescenz VA Medical Center
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Varenicline oral medication for smoking cessation | Guideline-based behavioral smoking cessation support |
|---|---|---|
| What it is | An oral medication (varenicline) approved for smoking cessation, being evaluated for its effectiveness and neurological impact in adults with schizophrenia or schizoaffective disorder who have tardive dyskinesia. | Behavioral counseling and support interventions recommended for smoking cessation in psychiatric populations, especially when pharmacologic therapy options are limited. |
| Role in the trial | Used as the sole intervention in this single-group study. All participants received varenicline while monitored for smoking cessation and neurological symptoms. | Not included as an arm in this study; represents the recommended approach for current care outside the trial. |
| Primary use | Used to facilitate smoking cessation in patients with schizophrenia or schizoaffective disorder and tardive dyskinesia. | Used to assist patients in quitting smoking through structured psychological and behavioral support without medication. |
| How it is given or performed | Varenicline is taken orally as a medication under supervision, with medical provider concurrence required for psychiatric participants. | Behavioral support involves individual or group counseling, motivational interviewing, and ongoing follow-up, typically delivered by mental health professionals or trained providers. |
| Evidence status | Investigational for effectiveness and safety in this specific population. Published controlled evidence is limited but registry and recent reviews indicate ongoing study. | Behavioral counseling is supported by guideline reviews and multiple controlled studies as effective for supporting smoking cessation in psychiatric disease, though absolute quit rates remain modest. |
| Important limitations | Potential risk for neuropsychiatric adverse effects and movement disorder worsening; contraindications include unstable psychiatric or neurological illness. Registry prohibits concomitant use of various medications and restricts to stable patients under provider oversight. Evidence base is limited in schizophrenia and TD. | Behavioral support is less effective than pharmacotherapy on average; relapse and modest absolute quit rates are commonly reported. May be less accessible for some patients, and behavioral methods alone do not address potential neuropsychiatric symptoms directly. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 2 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 weeks
Participants are observed for 2 weeks before starting treatment to assess smoking status and neurological symptoms.
1 visit (in-person)
Duration - 12 weeks
Participants receive varenicline to support smoking cessation while being monitored for changes in neurological symptoms and smoking behavior.
Weekly visits for 5 weeks, then 1 visit at week 12
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Stanley N Caroff, Rebecca Martine, Galit Kleiner-Fisman...
https://pubmed.ncbi.nlm.nih.gov/16364675/Stanley N Caroff, Patricia Walker, Cabrina Campbell...
https://pubmed.ncbi.nlm.nih.gov/17388711/Maryka Quik, Tanuja Bordia, Danhui Zhang...
https://pubmed.ncbi.nlm.nih.gov/26472532/Tanuja Bordia, Danhui Zhang, Xiomara A Perez...
https://pubmed.ncbi.nlm.nih.gov/27658674/Stanley N Caroff, Vicki G Davis, Del D Miller...
https://pubmed.ncbi.nlm.nih.gov/20816031/Stanley N Caroff, E Cabrina Campbell, Benjamin Carroll
https://pubmed.ncbi.nlm.nih.gov/28727483/Stanley N Caroff, E Cabrina Campbell
https://pubmed.ncbi.nlm.nih.gov/27514296/Corporal Michael J. Crescenz VA Medical Center
Lead Sponsor